secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023851
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca Q3 2022 net loss $35.5M; cash $365.5M funds ops into H2 2024
-------------------------------------------------------------------

- Net loss $35.5M ($0.29/sh) vs $46.1M ($0.46/sh) in Q3 2021; R&D spend $28.2M.
- Cash, cash equivalents & marketable securities $365.5M as of Sep 30, 2022; expects to fund operations into H2 2024.
- Positive preliminary monotherapy data for ERAS-007 and ERAS-601: 23% response in RAS/MAPK-altered non-CRC solid tumors.
- Entered CTCSAs with Lilly (cetuximab + ERAS-601) and Pfizer (palbociclib + ERAS-007); strategic R&D collaboration with MD Anderson.
- Upcoming milestones: IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 by year-end 2022; combo data for ERAS-007/601 in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/0000950170-22-023851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/eras-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer